Wegovy® tablets and headache

Where a tablet headache figure can be found

The US Prescribing Information covers the injection and the tablet in one document. For the tablet, section 6.1 describes Study 7: 204 adults without type 2 diabetes took the 25 mg tablet for up to 64 weeks, followed by seven weeks off the drug. Instead of printing a table for that study, the label states that the common reactions it found were similar in kind and frequency to those in Table 3, which comes from three injection trials of 2.4 mg. ^[1]

Study 7 is the trial published as OASIS 4. Its abstract reports weight and digestive results but no headache figure. ^[4] The individual numbers appear in the results the sponsor posted on ClinicalTrials.gov, which list every non-serious event reported by at least 5% of either group from week 0 to week 71. ^[3] The EU product information adds a frequency band. ^[2]

A three-point gap, read in context

On the registry figures, about 12 in 100 tablet users and 9 in 100 placebo users reported a headache during the study. The extra share on the tablet is roughly 3 percentage points, far below the gaps for nausea (46.6% against 18.6%) or vomiting (30.9% against 5.9%) in the same trial. ^[2] One tablet user had a headache classed as a serious adverse event; the record gives no detail about it. ^[3]

The placebo column is a reminder of how ordinary headaches are. The same record shows that many participants had common infections during the trial: COVID-19 in 20.1% on the tablet and 17.6% on placebo, colds (nasopharyngitis) in 21.1% and 26.5%, and influenza in 7.4% and 9.8%. ^[3] MedlinePlus lists colds, flu and fever among everyday causes of headache. ^[5] None of this tells you whether a particular headache came from the tablet, which is why a record of timing helps.

On timing, the EU document marks headache with the same footnote it uses for nausea and vomiting: mainly seen during dose escalation. ^[2] The US label builds the tablet up from 1.5 mg in days 1 to 30, through 4 mg and 9 mg, to 25 mg from day 91, and lets the prescriber delay a step if a dose is not tolerated. ^[1] Novo Nordisk’s tablet guide notes that side effects may be more noticeable at the start of a new dose and that a prescriber may keep you on one strength for longer than 30 days. ^[6]

What could connect the tablet and a headache

• Fluid loss, which the label warns about: digestive reactions were very common with the tablet, including nausea and vomiting, ^[2] and the Medication Guide says diarrhoea, nausea and vomiting can lead to dehydration and that drinking fluids helps lower that risk. ^[1] Cleveland Clinic describes dehydration headaches as coming with darker urine, a dry mouth and tiredness. ^[7] The label does not itself call headache a sign of dehydration, so treat this link as general background.
• Low blood sugar, mainly in type 2 diabetes: the Medication Guide includes headache among signs of low blood sugar, a risk that rises with insulin or a sulfonylurea. ^[1] Wegovy® tablets have not been studied for weight reduction in adults with type 2 diabetes (section 8.6). ^[1] The separate page on low blood sugar with the tablet covers this in detail.
• Not described: neither the US nor the EU document proposes a direct mechanism by which semaglutide causes headache. Its placement in the dose-escalation footnote is a timing pattern, not an explanation. ^[2]

Headaches that have nothing to do with the tablet

MedlinePlus describes tension headache, linked to tight muscles, stress or holding the head and neck awkwardly, as the most common type. Migraine tends to throb on one side and may come with sensitivity to light or nausea; lack of sleep and alcohol are among its listed triggers. Using pain medicine on more than three days a week can itself lead to rebound headaches, and premenstrual syndrome is another everyday cause. ^[5]

Rarely, a headache signals something serious: very high blood pressure, bleeding in or around the brain, an infection such as meningitis, carbon monoxide poisoning or sleep apnoea. ^[5] Separately, the EU product information lists a very rare optic nerve condition (NAION) with semaglutide and asks for an eye examination after any sudden loss of vision. ^[2] A headache that arrives with vision changes belongs in the emergency rows below, not in a wait-and-see diary.

Pain relievers, water and the morning routine

The Wegovy® label does not name a pain reliever. What it does set out is the tablet routine: one tablet on an empty stomach in the morning with no more than 4 ounces (about 120 mL) of plain water, then at least 30 minutes before food, other drinks or other oral medicines. ^[1] The EU interaction study explains why: taken alongside five other tablets, semaglutide exposure fell by 34%. ^[2] A headache tablet swallowed with your Wegovy® tablet is therefore exactly what the label asks you to avoid.

For tension headaches, MedlinePlus lists acetaminophen, aspirin or ibuprofen and asks you to talk to a provider if you need pain medicine three or more days a week. ^[5] The Medication Guide asks you to tell your provider about every over-the-counter medicine, since the label explains that Wegovy® delays stomach emptying, which can change how some tablets and capsules are handled. ^[1] Your pharmacist can say which option fits your other conditions and medicines.

The small amount of water belongs to the dose itself. After 30 minutes, the Medication Guide says you can eat and drink, and it describes drinking fluids as a way to lower the chance of dehydration. ^[1] MedlinePlus adds water (especially after vomiting), rest in a quiet dark room, a cool cloth and relaxation techniques, and suggests a diary of when each headache began, what you ate, drank and slept, and what eased it. ^[5]

Wegovy® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.

When to get help